S&P 500
7,551.60
+0.02%
Dow Jones
52,543.70
+0.06%
Nasdaq 100
29,760.70
+0.04%
Russell 2000
2,990.76
+0.00%
FTSE 100
10,480.00
-0.33%
Nikkei 225
68,939.70
-0.13%
Hims & Hers

Hims & Hers (HIMS) Q1 2026 Earnings

Reported May 11, 2026 at 4:08 PM ET · SEC Source

Q1 26 EPS

$-0.40

MISS 1,266.18%

Est. $0.03

Q1 26 Revenue

$608.1M

MISS 1.42%

Est. $616.9M

vs S&P Since Q1 26

+20.0%

BEATING MARKET

HIMS +21.9% vs S&P +1.8%

Market Reaction

Did HIMS Beat Earnings? Q1 2026 Results

Hims & Hers Health delivered a bruising first quarter for fiscal 2026, posting a net loss of $92.11 million, or $0.40 per diluted share, against a consensus estimate of $0.03, a miss of more than 1,266%, as a sweeping strategic pivot in its U.S. Weig… Read more Hims & Hers Health delivered a bruising first quarter for fiscal 2026, posting a net loss of $92.11 million, or $0.40 per diluted share, against a consensus estimate of $0.03, a miss of more than 1,266%, as a sweeping strategic pivot in its U.S. Weight loss business hit earnings hard. Revenue came in at $608.10 million, up 3.8% year-over-year but slightly below the $616.85 million consensus, as the company transitioned away from compounded GLP-1 medications toward branded alternatives, triggering $33.49 million in restructuring charges that helped push GAAP gross margin down to 65% from 73% a year ago. The repositioning also contributed to a sharp swing from net income of $49.48 million in Q1 2025. Adjusted EBITDA fell to $44.28 million from $91.06 million, yielding a 7% margin. Still, subscribers grew 9% year-over-year to nearly 2.6 million, and international revenue surged 969% to $78.19 million. Management raised full-year 2026 revenue guidance to $2.80 billion to $3.00 billion, signaling confidence that the GLP-1 transition will accelerate results through the back half of the year, and separately announced a new $250 million share repurchase authorization.

Key Takeaways

  • • Subscriber growth of 9% year-over-year to nearly 2.6 million
  • • Explosive international revenue growth of 969% year-over-year
  • • Strategic pivot in U.S. weight loss offering to branded GLP-1 medications
  • • Monthly revenue per average subscriber declined 6% to $80 from $85

HIMS Forward Guidance & Outlook

For Q2 2026, Hims & Hers expects revenue of $680 million to $700 million and Adjusted EBITDA of $35 million to $55 million (5%–8% margin). For full year 2026, the company raised revenue guidance to $2.8 billion to $3.0 billion with Adjusted EBITDA of $275 million to $350 million (10%–12% margin). All guidance excludes potential contributions from the proposed acquisition of Eucalyptus, expected to close mid-2026. Management reiterated long-term 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.

24/7 Wall St

HIMS YoY Financials

Q1 2026 vs Q1 2025, source: SEC Filings

24/7 Wall St

HIMS Revenue by Segment

With YoY comparisons, source: SEC Filings

Q2 22 Q1 26
24/7 Wall St

HIMS Revenue by Geography

With YoY comparisons, source: SEC Filings

Q4 25 Q1 26

“2026 is a defining year for Hims & Hers. We're not just growing, we're pulling away from the field on our path to becoming the world's largest consumer health platform. As we exit the first quarter, our domestic business is accelerating, we're expanding into new categories and countries, and more people than ever are relying on us for access to personal, data-driven care. We're investing with conviction in comprehensive diagnostics and a technology infrastructure built to make every interaction smarter than the last. The demand for a simpler, more personal path to feeling great has never been stronger, and Hims & Hers is increasingly the answer.”

— Andrew Dudum, Q1 2026 Earnings Press Release

Back to HIMS Stock Page